Related Experiment Video

Updated: Feb 15, 2026

Manual Restraint and Common Compound Administration Routes in Mice and Rats
14:10

Manual Restraint and Common Compound Administration Routes in Mice and Rats

Published on: September 26, 2012

301.1K

Pharmacokinetics, tissue distribution, and excretion of FGF-21 following subcutaneous administration in rats

Yufei He1, Yazhuo Li2, Zihong Wei2

  • 1Shenyang Pharmaceutical University, Shenyang, China.

Drug Testing and Analysis
|February 6, 2018
PubMed

Insights

Fibroblast growth factor 21 (FGF-21) shows linear pharmacokinetics, with rapid absorption and slow elimination. The kidney is the primary distribution organ, and urinary excretion is the main elimination route.

Area of Science:

  • Biochemistry
  • Pharmacology
  • Endocrinology

Background:

  • Fibroblast growth factor 21 (FGF-21) is a key regulator of glucose and lipid metabolism.
  • FGF-21 demonstrates potential therapeutic benefits for cardiovascular disease.
  • Pharmacokinetic data for FGF-21 in vivo is currently lacking.

Purpose of the Study:

  • To establish analytical methods for quantifying FGF-21.
  • To elucidate the in vivo pharmacokinetic profile of FGF-21.
  • To provide data for future safety and toxicology studies.

Main Methods:

  • Development of radioactivity assay and HPLC-based methods.
  • Quantification of 125I-labeled FGF-21 in plasma, tissues, and excrement.
  • Analysis of absorption, distribution, metabolism, and excretion (ADME) properties.

Main Results:

  • FGF-21 exhibited rapid systemic absorption and slow elimination.
  • Pharmacokinetics followed a linear, dose-dependent pattern (Cmax and exposure).
  • The kidney was the primary tissue for FGF-21 distribution; urinary excretion was the main elimination route.

Conclusions:

  • The study successfully characterized the in vivo pharmacokinetic behavior of FGF-21.
  • Findings indicate linear pharmacokinetics and highlight the kidney's role in distribution and urine in elimination.
  • This research provides crucial data supporting the development of FGF-21 as a therapeutic agent.
Keywords:
FGF-21excretionpharmacokineticstissue distribution

More Related Videos

Human Subcutaneous Adipose Tissue Sampling Using a Mini-Liposuction Technique08:59

Human Subcutaneous Adipose Tissue Sampling Using a Mini-Liposuction Technique

Published on: September 27, 2021

3.8K
Protective Efficacy and Pulmonary Immune Response Following Subcutaneous and Intranasal BCG Administration in Mice06:32

Protective Efficacy and Pulmonary Immune Response Following Subcutaneous and Intranasal BCG Administration in Mice

Published on: September 19, 2016

11.1K

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
279
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion01:18

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion

In geriatric patients, renal physiology undergoes significant changes, including diminished renal blood flow and a lower glomerular filtration rate (GFR), leading to alterations in medication clearance. Drugs such as aminoglycoside antibiotics, lithium, and digoxin, which rely on glomerular filtration for removal from the body, particularly impact pharmacokinetics. These drugs tend to have slower clearance rates in older adults, necessitating careful dosage considerations.Evaluation of renal...
261
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
197
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
334
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution01:00

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution

Drug distribution in the human body is influenced by several factors, including plasma protein concentration, body composition, blood flow, tissue-protein concentration, and tissue fluid pH. Among these, changes in plasma protein concentration and body composition due to aging significantly affect how drugs are distributed within the body. Specifically, aging is associated with a decrease in albumin levels by about 10% and an increase in α1-acid glycoprotein levels. These alterations are...
267
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
300